

1        Tuning the endothelial response: differential  
2        release of exocytic cargos from Weibel-Palade  
3        Bodies.

4  
5        Thomas D. Nightingale<sup>1</sup>, Jessica J. McCormack<sup>2</sup>, William Grimes<sup>2, 3</sup>,  
6        Christopher Robinson<sup>1</sup>, Mafalda Lopes da Silva<sup>2</sup>, Ian J. White<sup>2</sup>,  
7        Andrew Vaughan<sup>2</sup>, Louise P. Cramer<sup>2</sup> and Daniel F. Cutler<sup>2†</sup>

8  
9        <sup>1</sup>Centre for Microvascular Research, William Harvey Research Institute, Barts  
10        and the London School of Medicine and Dentistry, Queen Mary University of  
11        London, Charterhouse Square, London EC1M6BQ, UK.

12        <sup>2</sup>MRC Laboratory of Molecular Cell Biology, University College London, Gower  
13        Street, London, WC1E6BT, UK.

14        <sup>3</sup>Imaging Informatics Division, Bioinformatics Institute, 30 Biopolis Street,  
15        Singapore.

16  
17  
18  
19        †Corresponding author

20  
21        Email [d.cutler@ucl.ac.uk](mailto:d.cutler@ucl.ac.uk)

22        Address: MRC Laboratory for Molecular Cell Biology, Cell Biology Unit and  
23        Department of Cell and Developmental Biology, UCL, Gower Street, London.  
24        WC1E6BT

25        Phone: +44 (20) 7679 7808

26  
27  
28  
29        Running title: Differential release from Weibel-Palade Bodies  
30

31

32

33

34

35

36

37

38

39

40

41

42

43 Essentials

- 44 • Endothelial activation initiates multiple processes, including haemostasis  
45 and inflammation
- 46 • The molecules that contribute to these processes are co-stored in  
47 secretory granules.
- 48 • How can the cells control release of granule content to allow  
49 differentiated responses?
- 50 • Selected agonists recruit an exocytosis-linked actin ring to boost release  
51 of a subset of cargo.

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68 Abstract

69 **Background:** Endothelial cells harbour specialised storage organelles, Weibel-  
70 Palade Bodies (WPBs). Exocytosis of WPB content into the vascular lumen  
71 initiates primary haemostasis, mediated by Von Willebrands factor (VWF) and  
72 inflammation, mediated by several proteins including P-selectin. During full  
73 fusion, secretion of this large haemostatic protein and smaller pro-inflammatory  
74 proteins are thought to be inextricably linked.

75

76 **Objective:** To determine if secretagogue-dependent differential release of WPB  
77 cargo occurs, and whether this is mediated by the formation of an actomyosin  
78 ring during exocytosis.

79

80 **Methods:** We used VWF string analysis, leukocyte rolling assays, ELISA, spinning  
81 disk confocal microscopy, high-throughput confocal microscopy and inhibitor  
82 and siRNA treatments to demonstrate the existence of cellular machinery that  
83 allows differential release of WPB cargo proteins.

84

85 **Results:** Inhibition of the actomyosin ring differentially effects two processes  
86 regulated by WPB exocytosis; it perturbs VWF string formation but has no effect  
87 on leukocyte rolling. The efficiency of ring recruitment correlates with VWF  
88 release; the ratio of release of VWF to small cargoes decreases when ring  
89 recruitment is inhibited. The recruitment of the actin ring is time-dependent;  
90 fusion events occurring directly after stimulation are less likely to initiate  
91 haemostasis than later events, and is activated by PKC isoforms.

92

93 **Conclusions:** Secretagogues differentially recruit the actomyosin ring, thus  
94 demonstrating one mechanism by which the pro-thrombotic effect of endothelial  
95 activation can be modulated. This potentially limits thrombosis whilst permitting  
96 a normal inflammatory response. These results have implications for the  
97 assessment of WPB fusion, cargo-content release and the treatment of patients  
98 with von Willebrand disease.

99

100 Keywords: Von Willebrand Factor, Weibel-Palade Bodies, Exocytosis,  
101 Hemostasis, Inflammation

102

103 Introduction

104 A rapid response to vascular injury or infection minimises blood loss and spread  
105 of pathogens. Endothelial rod-shaped storage organelles called Weibel-Palade  
106 bodies (WPB) harbour multiple pre-made, pro-inflammatory and pro-  
107 haemostatic proteins[1-3], including the leukocyte receptor P-selectin, the pro-  
108 haemostatic glycoprotein Von Willebrands factor (VWF), pro-inflammatory  
109 cytokines, and agents that control tonicity[4]. Some cargos are up-regulated after  
110 endothelial activation including IL-8[5, 6] and angiopoietin-2[7]. Within minutes  
111 of secretagogue stimulation WPBs undergo exocytosis[8, 9], releasing their  
112 content into the blood which initiates haemostasis and leukocyte recruitment[2].

113

114 Release of VWF and P-selectin have distinct functional consequences. VWF  
115 multimers are stored in multi-concatamer coiled proteinacious tubules, together  
116 with their cleaved pro-peptides[10]. Upon exocytosis, the tubules unfurl into  
117 long protein strings, that recruit platelets even at non-pathological shear[11, 12].

118 VWF mutations, or defective cellular machinery cause incorrect processing and  
119 can underlie bleeding disorders[13]. Animal models of or patients with low VWF  
120 exhibit a decreased incidence of atherosclerosis[14]. Conversely excess ultra-  
121 high molecular weight VWF in the bloodstream (due to induced or genetic  
122 absence of the VWF-cleaving metalloprotease ADAMTS13), results in the  
123 microvascular occlusions[15] of thrombotic thrombocytopenic purpura, and  
124 patients with elevated plasma VWF have an increased risk of cardiac events[14,  
125 16] and stroke[17]. VWF is thus a key factor in cardiovascular disease. P-selectin  
126 is a leukocyte receptor that mediates initial rolling of leukocytes on the vascular  
127 endothelium[18-20]. Loss or inappropriate clustering of P-selectin at the  
128 endothelial cell surface results in immunodeficiency due to a failure to recruit  
129 leukocytes[20, 21].

130

131 Being co-stored, parallel release at exocytosis of VWF and smaller components  
132 such as P-selectin should be obligatory. However, there is evidence of differential  
133 release of VWF [22-24]. At low extracellular pH unfolding of VWF is prevented  
134 such that only small soluble components are released[22], whilst in lingering  
135 kiss fusion, comprising about 10% of fusion events after strong histamine  
136 stimulation[23], only cargo proteins  $\leq 40$ kDa are released. However, neither of  
137 these mechanisms enables differential release of VWF vs P-selectin and therefore  
138 the segregation of inflammatory and haemostatic effects. Furthermore, no  
139 molecular machinery providing physiological control of VWF release has been  
140 identified.

141

142 Recent research has uncovered machinery controlling the efficiency of VWF  
143 release from WPBs [9, 25, 26]. If differentially recruited by agonists, this would  
144 potentially promote regulated release of pro-haemostatic VWF whilst not  
145 altering release of smaller pro-inflammatory components. Such “differential  
146 release”, a novel layer of regulation, could limit potentially dangerous  
147 thrombosis whilst allowing a normal inflammatory response. We have used  
148 multiple *in vitro* assays to show that recruitment of an actomyosin ring allows  
149 differential release of cargo following stimulation by numerous physiologically-  
150 relevant secretagogues. We also describe protein kinase-C as upstream  
151 machinery that modulates its recruitment.

152

## 153 Methods

### 154 **Cell culture and nucleofection**

155 HUVECs were cultured as described previously[27]. GFP-VWF[28] was from J.  
156 Voorberg and J.A. Van Mourik (Sanquin Research Laboratory, Amsterdam,  
157 Netherlands). P-sel.Lum-mCherry was previously described [9] Lifeact-GFP[29]  
158 was from B. Baum (University College London, UK). GFP-tagged PKC $\alpha$  and PKC $\beta$   
159 were gifts from A. Poole (University of Bristol, UK), GFP-tagged PKC $\delta$  and PKC $\epsilon$   
160 were from P. Parker (Francis Crick Institute, London, UK). DNA (1–5  $\mu$ g) was  
161 nucleofected using program U-001 (Lonza). Cells were typically assayed 24 h  
162 post-transfection.

### 163 **Immunofluorescence**

164 This was detailed previously[9].

165 **Secretion assay and ELISA**

166 HUVECs were incubated with 1  $\mu\text{M}$  CCE, 25  $\mu\text{M}$  blebbistatin (Sigma-Aldrich) for  
167 5–15 min before determining VWF or pro-peptide release in the presence or  
168 absence of 100 ng/ml PMA (Sigma-Aldrich), 100  $\mu\text{M}$  histamine or 100  $\mu\text{M}$   
169 histamine/10  $\mu\text{M}$  adrenalin/ 100  $\mu\text{M}$  IBMX and/or the relevant drug for 30 min.  
170 VWF secretion assay and ELISAs have been described previously[30][31]. For  
171 VWF pro-peptide secretion an ELISA kit (Mast Group Ltd) was used according to  
172 the manufacturer's instructions.

173 **Exocytic site labelling assay**

174 Exocytic site labelling was performed using a modified method from Knop and  
175 Gerke, 2002 [32]. Confluent cells grown on 96 well plates (Nunc) for two days  
176 were washed in pre-warmed release medium (M199 with 0.2% BSA and 10mM  
177 HEPES), and where necessary incubated with CCE or blebbistatin as for secretion  
178 assays. Cells were incubated for 2-20 minutes in the presence of rabbit anti-VWF  
179 and either unstimulated, or stimulated with PMA (6.25-100ng/ml), histamine  
180 (100  $\mu\text{M}$ ), thrombin (1U/ $\mu\text{l}$ ), VEGF (40ng/ml), Forskolin (10 $\mu\text{M}$ ), ATP (100 $\mu\text{M}$ ),  
181 or adrenalin (10  $\mu\text{M}$ )/IBMX (100  $\mu\text{M}$ ), either alone or in combination, in release  
182 medium. Cells were incubated with wheat germ agglutinin (Life Technologies)  
183 for two minutes on ice or fixed immediately in 4% paraformaldehyde,  
184 permeabilised with 0.2% Triton X-100 in PBS and incubated with mouse anti-  
185 VE-cadherin (BD biosciences) or with secondary antibodies conjugated to Alexa  
186 Fluor 488- or 647-nm and Hoescht 33342.

187 **High-throughput image acquisition and segmentation.**

188 Cells were cultured, fixed and stained in 96-well plates then imaged with the  
189 Opera high-content screening (PerkinElmer) confocal microscope using a 40× air  
190 objective lens (NA 0.6). Datasets comprise 864 images (nine fields of view per  
191 well), approximately 10,000 cells. Analysis used Python2.7, with the scikit-image  
192 library[33]. Image noise was reduced by Gaussian blurring, then a binary mask  
193 was created using a threshold value from Moment-preserving thresholding[34].  
194 Adjacent sites were split using the marker-based watershed flooding algorithm.  
195 Segmented objects beneath the resolution limit of the optical system were  
196 removed. Finally, morphometric measurements were taken. Segmentation was  
197 validated by comparison to a set of manually-annotated images. Data analysis  
198 was conducted in the R programming language version 3.2[35].

#### 199 **Western blotting**

200 This was carried out as described previously[9].

#### 201 **Live-cell imaging**

202 Nucleofected cells stimulated with PMA, histamine, or  
203 histamine/adrenalin/IBMX were visualized as detailed previously using a 100×  
204 oil immersion lens (NA 1.4) on a spinning-disk system (UltraVIEW VoX;  
205 PerkinElmer)[9].

#### 206 **VWF string analysis and quantification**

207 String assays were carried out as described previously[9].

#### 208 **Rolling assay and quantification**



209 HUVECs prepared as for string assays were placed on the stage of an Axiovert  
210 200M microscope at 37°C, connected to a syringe pump, and HBSS media  
211 perfused for 2 minutes at a constant wall shear stress 0.07Pa (0.7 dyne/cm<sup>3</sup>).  
212 HUVECs were then either perfused with HBSS alone or stimulated with  
213 histamine/adrenaline/IBMX in the presence or absence of CCE (0.25 μM) for five  
214 minutes before being perfused with THP-1 cells (0.5 x 10<sup>6</sup>/ml) in HBSS in the  
215 presence or absence of secretagogue. Videos were recorded using a Rolera Bolt  
216 CMOS camera (QImaging) using MicroManager software. Videos were analysed  
217 using ImageJ. Interacting THP-1 cells were defined as those seen to pause on the  
218 endothelial monolayer and counted manually.

#### 219 **Cell surface biotinylation assay**

220 This was carried out as described previously[21].

221

#### 222 Results

223 We and others demonstrated that VWF release is boosted by a contractile  
224 actomyosin ring forming around the fused WPB to squeeze out content [9, 25,  
225 26], but whether this boost affects platelet and leukocyte recruitment to  
226 endothelial cells was undetermined. We first analysed the effect of actomyosin  
227 ring inhibition on VWF string formation (Fig. 1A-C). HUVECs grown in flow  
228 chambers were briefly treated with a low dose (thus without an effect on cell  
229 viability or adherence) of the actin depolymerising drug cytochalasin E (CCE)  
230 which binds to the barbed end of the actin chain[36]. A cocktail (to stimulate  
231 both calcium and cAMP-mediated pathways of WPB exocytosis) of histamine,  
232 adrenalin and 3-isobutyl-1-methyl xanthine (IBMX) was used to stimulate WPB

233 exocytosis and the length of resulting strings was analysed. In cells treated with  
234 CCE the formation of long strings was significantly reduced (Fig. 1A-C). To  
235 determine if leukocyte recruitment is also reduced we monitored rolling in the  
236 presence or absence of CCE. We saw no significant difference in the frequency of  
237 rolling leukocytes following drug treatment (Fig. 1D; video 1-3). Thus in a  
238 controlled system, inhibition of the actomyosin ring differentially affects  
239 inflammatory vs. haemostatic functioning. We hypothesise that the regulation of  
240 VWF secretion by the actomyosin ring is a secretagogue-dependent way to bias  
241 the endothelial response to be more or less haemostatic.

242

243 VWF is by far the largest WPB cargo protein, likely requiring the most physical  
244 force for efficient release, potentially explaining why control of the actin ring  
245 specifically affects haemostatic responses. Similarly, smaller pro-inflammatory  
246 content should be less affected by actin ring inhibition (Fig. 2A-B). Further, to  
247 provide physiological regulation, different secretagogues should differentially  
248 utilise the actin ring. To test this we used three secretagogues which activate  
249 different downstream signalling pathways[4]; PMA, histamine, and  
250 histamine/adrenalin/IBMX. To determine the effect of content size on its  
251 efficiency of release, we compared secretion of VWF (large cargo) (Fig. 2Ci) with  
252 VWF pro-peptide (small cargo) (Fig. 2Cii). The pro-peptide is necessarily co-  
253 packaged in equi-molar amounts with VWF, thus providing exact ratiometric  
254 data. Further, the pro-peptide is increasingly used clinically to determine VWF  
255 clearance [37], thus evidence of its differential release is of intrinsic interest.  
256 Whilst PMA and histamine/adrenalin/IBMX were similarly effective at  
257 exocytosing both large and small content, histamine releases the large cargo

258 VWF much less efficiently than PMA. This was most clearly apparent when  
259 presented as the ratio of VWF/pro-peptide release to give a measure of the  
260 secretion efficiency of large vs small cargo (Fig. 2Ciii).

261

262 To determine if this difference in efficiency depends on the actomyosin  
263 machinery we used CCE to inhibit actin polymerisation and blebbistatin[38] to  
264 block non-muscle myosin II contraction (Fig. 2D). CCE completely inhibits ring  
265 formation whilst blebbistatin reduces the rate of ring contraction. As predicted,  
266 efficient release of VWF following PMA stimulation requires the actomyosin ring;  
267 these inhibitors reduced VWF release (Fig. 2Di). Conversely, release of the  
268 smaller VWF pro-peptide is essentially actin ring-independent (Fig. 2Dii). The  
269 ratio of VWF to pro-peptide release following PMA stimulation is  $0.4 \pm 0.05$ ,  
270 whilst in cells which cannot recruit the ring, efficiency of release falls to  $0.2 \pm 0.04$   
271 (Fig. 2Diii). Interestingly, PMA-stimulated cells in which the actin ring is  
272 inhibited behave similarly to histamine-stimulated cells in terms of efficiency of  
273 VWF release. This data shows that the actomyosin ring provides a means for  
274 secretagogue-dependent control of VWF release without affecting smaller cargo.

275

276 We next addressed whether the actomyosin ring influenced the delivery of  
277 integral membrane proteins to the cell surface from WPBs. We stimulated  
278 HUVECs with different secretagogues and monitored P-selectin appearance on  
279 the plasma membrane (Fig. 3A & C). The most efficient delivery to the plasma  
280 membrane occurred following PMA stimulation, whereas histamine and  
281 histamine/adrenalin/IBMX behave similarly. The delivery of P-selectin to the cell  
282 surface in response to PMA was partially dependent on the actomyosin ring as

283 both blebbistatin and CCE reduced cell surface levels (Fig. 3B & D). The reason  
284 for this is unclear but might reflect VWF/P-selectin binding, retaining P-selectin  
285 within the WPB after fusion [39]. Consistent with this, as reported, P-selectin is  
286 enriched along VWF strings [40] and at exocytic sites post-exocytosis (Fig. S1,  
287 Fig. 3E). Alternatively, the partial inhibition could reflect a steric hindrance of the  
288 extracellular domain of P-selectin as it exits the fusion pore; P-selectin mobility  
289 is limited in mature WPBs [41]. Therefore, the delivery of larger integral  
290 membrane proteins can be influenced by inhibition of the actin ring although not  
291 enough to inhibit function (Fig 1D).

292

293 To directly determine the extent and kinetics of actin ring recruitment, we  
294 monitored actin ring recruitment in live cells [9]. We monitored the loss of  
295 mcherry-Pselectin.lum (marking WPB fusion) and the recruitment of lifeact-GFP  
296 (tracking ring assembly) and found (Fig. 4A) that approximately  $\approx 15\%$  of  
297 histamine-stimulated fusion events,  $\approx 40\%$  of histamine/adrenalin/IBMX-  
298 stimulated events and  $\approx 65\%$  of PMA-stimulated events recruit the ring.  
299 Additionally, the probability of ring recruitment increases over time (Fig. 4B).  
300 Immediately following stimulation (0-50s), and irrespective of secretagogue, the  
301 likelihood of recruitment is low. For PMA and histamine/adrenalin/IBMX-  
302 stimulated cells this is followed by increased ring recruitment (50-200s) (68%  
303 and 69% of events are actin-positive in PMA and histamine/adrenalin/IBMX-  
304 stimulated cells respectively over 100-600s). In histamine-stimulated cells the  
305 majority of events are actomyosin ring-independent, although the percentage of  
306 actin-positive events increases over time, until every event recruited a ring  
307 (though few events occur at these later times). Therefore time-dependent

308 phenomena are likely required for ring recruitment, presumably including both  
309 signalling and recruitment of machinery.

310

311 We next sought to determine whether recruitment of the actomyosin ring  
312 following stimulation by the many established WPB secretagogues [4, 42] both  
313 alone and in combination is a major feature of exocytosis. We developed an assay  
314 for determination of the size of the fusion site. This assay takes advantage of  
315 information obtained previously using correlative light and electron microscopy  
316 and scanning electron microscopy showing that levels of exocytosed, antibody -  
317 accessible VWF is dependent on the actomyosin ring[9]. We added anti-VWF  
318 antibody to the media to retain VWF at exocytic sites (and prevent string  
319 formation) [32, 43] to analyse exocytic site formation in thousands of cells. We  
320 hypothesised that more efficient release mediated by the actin ring is likely to  
321 result in bigger sites (Fig. 5B), and developed an automated segmentation  
322 protocol to acquire a set of morphological measurements for each site from 72  
323 fields of view (950-1200 cells) analysed per condition (Fig. 5A).

324

325 This approach is unbiased, automated, and highly sensitive, as shown by our  
326 analyses revealing that the number of sites increased in response to increased  
327 PMA in a dose-dependent manner (Fig. S2Aa), without change to the site area  
328 (Fig. S2Ab). Thus, even at a high density, segmentation of individual sites is not  
329 compromised. Histamine elicits a rapid response, typically complete by 10  
330 minutes post-stimulation, whereas PMA produces a more linear release of VWF  
331 [44]. Importantly, these biochemical dynamics were replicated in our assay,  
332 which is sensitive enough to distinguish differences in the number of exocytic

333 sites over discrete two-minute periods (Fig. 5C). To verify the assay could  
334 differentiate ring-dependent and independent exocytic events we monitored the  
335 number (Fig. 5D) and area of sites (Fig. 5E) and noted that sites segmented from  
336 stimulated cells were significantly larger than those from unstimulated cells, and  
337 that PMA-stimulated cells produce larger sites than histamine-stimulated cells –  
338 correlating with actin ring recruitment. We therefore analysed changes in  
339 histamine and PMA-stimulated cells treated with blebbistatin and CCE to  
340 determine the effect of actin ring inhibition on the proportion of large exocytic  
341 sites (classified as those greater than  $2\mu\text{m}^2$ ) (Fig. 5G, Fig. S2B). CCE treatment  
342 specifically reduces the proportion of larger exocytic sites following both PMA  
343 and histamine stimulation, whilst blebbistatin, as expected, had little effect (as it  
344 slows rather than completely inhibits actomyosin ring contraction). This effect  
345 was greatest in PMA-stimulated cells (Fig. 5G, Fig. S2B). Together this validates a  
346 new, sensitive, high-throughput method of monitoring VWF exocytic sites  
347 suitable for screening secretagogues for their ability to recruit the actomyosin  
348 ring.

349

350 We then surveyed different secretagogues for their use of the actomyosin ring.  
351 By determining the number (Fig. 6A, Fig. S3A & B) and size of exocytic sites (Fig.  
352 6B-D, Fig. S3C & D) following stimulation with different secretagogues in  
353 isolation or combination, we found significant differences in actin ring  
354 recruitment (Fig. 6C & D, Fig. S3C-F). Whilst, thrombin relies minimally on the  
355 actin ring for release of VWF, PMA, VEGF, histamine/adrenalin/IBMX and  
356 forskolin are strong ring recruiters (correlating with ours and others' findings [9,  
357 25]). We also find that actin ring recruitment can be enhanced via addition of

358 some, but not all, Calcium or cAMP-raising agents (Fig. 6 & Fig S3), which is  
359 consistent with our earlier ELISA data. Our approach provides large quantitative  
360 datasets to reveal actin ring-dependence for a range of secretagogues and  
361 indicates for the first time that endothelial cells, by responding to physiological  
362 cues, have the capability to tune the release of cargo content.

363

364 We next sought the upstream machinery required for actin ring recruitment.  
365 Actin-dependent exocytic structures occur in the cortical granules of *Xenopus*  
366 oocytes, the zymogen granules of the pancreatic and parotid acinar and the  
367 lamellar bodies of type II pneumocytes[45]. Some of these granules utilise  
368 protein kinase C (PKC) isoforms to recruit an actin ring[46, 47]. Given this, and  
369 that PMA (an activator of classical and non-classical PKC isoforms) recruits the  
370 actin ring most efficiently, we analysed the role of PKC in ring recruitment.

371

372 PKC $\alpha$ , PKC $\delta$ , PKC $\epsilon$ , PKC $\eta$  and PKC $\zeta$  are expressed in HUVECs [48]. Live-cell  
373 imaging of individual fusion events using mCherry-P-selectinLum as a marker of  
374 fusion and various human GFP-tagged versions of PKC showed recruitment of  
375 PKC $\alpha$  and PKC $\delta$  on the actin ring (Fig. 7A & B) but not epsilon, nor beta (not  
376 endogenously expressed; data not shown) suggesting specific recruitment.  
377 Recruitment of PKC prior to the actin ring is consistent with a role upstream of  
378 or during initiation of ring recruitment. (Fig. S4). To assess the function of these  
379 isoforms in VWF release from PMA-stimulated cells we depleted either PKC $\alpha$  or  
380 PKC $\delta$  (Fig. 7C) and monitored VWF release by ELISA. PKC $\alpha$  but not PKC $\delta$   
381 knockdown had a marked effect (Fig. 7D).

382

383 Finally, we monitored the effect of an inhibitor of PKC $\alpha$  on VWF secretion (Fig.  
384 7E). Predictably, PKC $\alpha$  inhibition had the strongest effect on PMA-stimulated  
385 release, a lesser effect on histamine/adrenalin/IBMX-stimulated release and no  
386 effect on histamine-stimulated release (Fig. 7E, Fig. S5A). We also noted some  
387 reduction in the number of exocytic sites seen in PMA-stimulated cells, with a  
388 lesser effect on histamine or histamine/adrenalin/IBMX (Fig. S5B & C). An  
389 additional role for PKC in exocytosis is thus possible alongside the formation of  
390 the actomyosin ring.

391

## 392 **Discussion**

393 We present here evidence for the differential release of WPB cargo that we  
394 speculate can allow the separation of haemostatic and inflammatory responses.  
395 We find that different secretagogues are differentially effective at recruiting an  
396 actomyosin ring to WPBs at exocytosis, and that recruitment of this ring  
397 correlates with the release of the largest WPB cargo protein, VWF. Ultimately  
398 this represents a new layer of control to facilitate greater regulation over the  
399 outcome of endothelial activation.

400

401 We firstly demonstrated that two functions ascribed to WPB cargo content can  
402 be differentially regulated. We used an *in vitro* flow chamber to separate effects  
403 on leukocyte adhesion from VWF string formation in endothelial cells treated  
404 with a low dose of the actin poison CCE. Recruitment of the actomyosin ring  
405 affected VWF string formation (and therefore the efficiency of platelet  
406 recruitment) (Fig. 1A-C) but not leukocyte recruitment (Fig. 1D).

407



408 To determine if this effect reflects size-specific control of the release of WPB  
409 cargo, we monitored release of equimolar co-packaged VWF multimers (large  
410 protein) versus VWF pro-peptide (small protein) in parallel. We found that only  
411 the release of VWF was differentially evoked by secretagogues, and that this  
412 correlated with the recruitment of an actin ring (Fig. 2). Stimulation with  
413 histamine alone was not efficient at releasing VWF relative to the pro-peptide,  
414 whereas PMA or histamine/adrenalin/IBMX were much more efficient (Fig. 2C).  
415 Similar reductions in efficiency followed perturbation of actomyosin ring  
416 function at PMA stimulation plus blebbistatin or CCE (Fig. 2D); squeezing by the  
417 actin ring is more important for larger cargoes than small ones, and this can  
418 explain some of the differences revealed by functional assays. The greater effects  
419 of CCE than blebbistatin likely reflects the fact that CCE inhibits ring formation  
420 whilst blebbistatin only slows the rate of its contraction.

421

422 Leukocyte rolling following secretagogue stimulation is initiated by P-selectin  
423 [19, 20] clustered at the cell surface by the WPB co-cargo CD63 [21]. CD63  
424 readily transfers to the plasma membrane even in situations where VWF release  
425 is inhibited, including release at low pH [22] or during lingering kiss fusion [23].  
426 Surface biotinylation demonstrated that P-selectin traffic to the cell surface is  
427 partially actomyosin ring-dependent (Fig. 3) although we see no difference in  
428 leukocyte rolling following actomyosin ring inhibition (Fig. 1D). Direct  
429 interactions with VWF (also suggested by imaging Fig. S1) may explain this effect  
430 [39]. The clustering effects of CD63, or a simple excess of receptor may help to  
431 mitigate the differences seen in P-selectin recruitment to the cell surface.

432

433 Directly imaging ring recruitment (Fig. 4) to determine which secretagogues  
434 recruit the ring to the greatest extent corroborated our ELISA results. Notably,  
435 we also identified a time-dependence to ring recruitment, with later exocytic  
436 events with all tested stimuli much more likely to recruit the ring. This  
437 intriguing time course suggests that downstream signalling is required both to  
438 recruit the actin ring and to localise associated cellular machinery.

439

440 The most efficient actin ring recruitment (and therefore VWF release) occurs  
441 when multiple secretagogues are used (Fig. 2 & 4). We utilised a new high-  
442 throughput approach to monitor a range of secretagogues (Fig. 5, 6 & S2).  
443 Assaying thousands of exocytic sites from thousands of cells, this approach  
444 affords excellent temporal sensitivity and statistical significance. *In vivo* the  
445 endothelium is likely stimulated by multiple secretagogues; histamine activation  
446 is accompanied by at least some adrenalin (resting levels are 0.31nM [49]).  
447 Identifying the signalling pathways downstream of secretagogue activation is  
448 complex, as many intersect. One of the strongest ring-promoting agents is the  
449 non-physiological DAG analogue PMA, suggesting PKC involvement (most likely  
450 PKC $\alpha$ ) (Fig. 7). Since PKC $\alpha$  can be activated directly by both DAG and Calcium  
451 [50] or indirectly via cAMP-dependent agonists and EPAC (exchange proteins  
452 directly activated by cAMP isoform) [51, 52] PKC activation could feasibly occur  
453 downstream of any of the ring-recruiting agonists that we, and others, have  
454 identified. The cAMP-raising secretagogues forskolin and adrenalin have  
455 previously been identified by others [25] as stimulating actin ring recruitment.  
456 Here we find that addition of adrenalin/IBMX to the Calcium-dependent  
457 secretagogue histamine significantly enhances ring recruitment, suggesting

458 activation of cAMP may be an important route to ring recruitment. Interestingly,  
459 thrombin, which is largely actin ring independent, can inhibit cAMP production,  
460 potentially explaining why this is a poor ring recruiter [53]. However, it is likely  
461 that other, as-yet-unidentified pathways independent of PKC $\alpha$  are also involved  
462 in ring recruitment. Histamine alone is able to recruit the actin ring, despite the  
463 fact that its mode of action is thought to be PKC-independent [48]. Although  
464 PKC $\alpha$  acts in ring recruitment, VEGF is also effective at recruiting the actin ring  
465 and acts via PKC $\delta$  (and VWF release is not inhibited by inhibition of PKC $\alpha$  in  
466 VEGF-stimulated cells) [48], thus roles for additional PKC isoforms are possible.

467

468 VWF release is not completely actin ring-dependent, as CCE treatment does not  
469 abolish it, and secretagogues that do not utilise the ring still expel VWF, albeit at  
470 a lower efficiency (Fig. 2-6) as measured by pro-peptide vs VWF release. Thus  
471 cargo expulsion may also be driven by water entry, changes in ionic fluxes or pH  
472 [54]. We have also found protracted actin ring formation and slower release of  
473 content at lowered external pH (data not shown). Other large acidified granules  
474 with viscous content including lamellar bodies, pancreatic and parotid acinar  
475 zymogen granules all require extra machinery to drive release [45], indicating  
476 that charge is not always the sole and most efficient driving force. Other large  
477 granules may also exhibit differential recruitment of actin rings and therefore  
478 differential release of content.

479

480 Our research complements recent research confirming that VWF release is  
481 boosted by an actomyosin ring[25, 26]. However, there are differences in the  
482 findings: We concluded that rings form *de novo* after fusion [9], whereas Han *et*

483 *al* report actin remodelling before fusion from a pre-existing framework. We also  
484 differ on whether WPB localisation is generally affected by Myosin II  
485 inhibition[9, 26]. The different conclusions might reflect which cell surface was  
486 imaged (apical versus basal) or spinning disk versus custom microscopy [9, 25].  
487 A role for some actin nucleation yet remains a possibility.

488

489 Differential release has previously been proposed, based on the presence of  
490 multiple pools of WPB [24]. While additional cargos can be added to WPB  
491 including IL-8[5, 6] and angiopoietin-2[7] we have no evidence to suggest the  
492 ring can be differentially recruited to distinct WPB containing different cargos;  
493 this would require cytoplasmic machinery detecting cargo stored internally in  
494 WPB.

495

496 Our results support the clinical use of VWF pro-peptide monitoring, perhaps  
497 immediately after agonist treatment, where needed. We also note that DDAVP,  
498 the secretagogue most commonly used to treat VWD patients, is cAMP-  
499 dependent [55] and perhaps this is one reason why it is an effective therapeutic  
500 choice.

501

502 In conclusion, these data provide evidence for an additional level of functional  
503 control of WPBs, concluding that endothelial cells may tune the haemostatic  
504 response via the recruitment of an actomyosin ring.

505

506 Addendum

507 JJM and TDN equally made the greatest contributions to this paper; both  
508 invented novel assays, designed and carried out experiments, analysed data and  
509 wrote the manuscript; CR, WG and MLS, designed and carried out experiments  
510 and contributed to the writing of this paper, IJW and AV provided technical  
511 expertise and analysed data, LPC and DFC designed research, analysed data and  
512 wrote the paper.

513

#### 514 Disclosure of Conflict of Interest

515 T. D. Nightingale was funded by a Medical Research Council project grant  
516 MR/M019179/1 and a British Heart Foundation project grant (PG/15/72/31732).  
517 J.J. McCormack and D.F. Cutler were funded by an MRC programme grant  
518 MC\_UU\_12018/2. I.J. White was funded by MRC LMCB core. W. Grimes was  
519 supported partly by the Biomedical Research Council of A\*STAR (Agency for  
520 Science, Technology and Research), Singapore, partly by the MRC LMCB. C.  
521 Robinson was funded by a BHF project grant (PG/15/72/31732). M. Lopes da Silva  
522 reports grants from MRC during the conduct of the study; and grants from MRC  
523 outside the submitted work. The other authors state that they have no conflict of  
524 interest.

525

526

527

528

529

530

531

532

533

534 References

- 535 1 Metcalf DJ, Nightingale TD, Zenner HL, Lui-Roberts WW, Cutler DF.  
536 Formation and function of Weibel-Palade bodies. *J Cell Sci.* 2008; **121**: 19-27.  
537 121/1/19 [pii]  
538 10.1242/jcs.03494.
- 539 2 Nightingale T, Cutler D. The secretion of von Willebrand factor from  
540 endothelial cells; an increasingly complicated story. *Journal of thrombosis and*  
541 *haemostasis : JTH.* 2013; **11 Suppl 1**: 192-201. 10.1111/jth.12225.
- 542 3 Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional  
543 architecture of Weibel-Palade bodies. *Blood.* 2011; **117**: 5033-43. blood-2010-  
544 09-267492 [pii]  
545 10.1182/blood-2010-09-267492.
- 546 4 Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and  
547 plasticity of Weibel-Palade bodies in endothelial cells. *Arteriosclerosis,*  
548 *thrombosis, and vascular biology.* 2006; **26**: 1002-7.
- 549 5 Utgaard JO, Jahnsen FL, Bakka A, Brandtzaeg P, Haraldsen G. Rapid  
550 secretion of prestored interleukin 8 from Weibel-Palade bodies of microvascular  
551 endothelial cells. *The Journal of experimental medicine.* 1998; **188**: 1751-6.
- 552 6 Wolff B, Burns AR, Middleton J, Rot A. Endothelial cell "memory" of  
553 inflammatory stimulation: human venular endothelial cells store interleukin 8 in  
554 Weibel-Palade bodies. *The Journal of experimental medicine.* 1998; **188**: 1757-62.
- 555 7 Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz  
556 W, Thurston G, Augustin HG. The Tie-2 ligand angiopoietin-2 is stored in and  
557 rapidly released upon stimulation from endothelial cell Weibel-Palade bodies.  
558 *Blood.* 2004; **103**: 4150-6. 10.1182/blood-2003-10-3685.
- 559 8 Erent M, Meli A, Moiso N, Babich V, Hannah MJ, Skehel P, Knipe L,  
560 Zupancic G, Ogden D, Carter T. Rate, extent and concentration dependence of  
561 histamine-evoked Weibel-Palade body exocytosis determined from individual  
562 fusion events in human endothelial cells. *J Physiol.* 2007; **583**: 195-212.
- 563 9 Nightingale TD, White IJ, Doyle EL, Turmaine M, Harrison-Lavoie KJ,  
564 Webb KF, Cramer LP, Cutler DF. Actomyosin II contractility expels von  
565 Willebrand factor from Weibel-Palade bodies during exocytosis. *The Journal of*  
566 *cell biology.* 2011; **194**: 613-29. jcb.201011119 [pii]  
567 10.1083/jcb.201011119.
- 568 10 Springer TA. von Willebrand factor, Jedi knight of the bloodstream. *Blood.*  
569 2014; **124**: 1412-25. 10.1182/blood-2014-05-378638.
- 570 11 De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von  
571 Willebrand factor strings puzzle. *Blood.* 2013; **121**: 270-7. blood-2012-07-  
572 442285 [pii]  
573 10.1182/blood-2012-07-442285.
- 574 12 Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN,  
575 Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly  
576 secreted ultralarge von Willebrand factor multimers on the endothelial surface  
577 under flowing conditions. *Blood.* 2002; **100**: 4033-9.

578 13 James PD, Lillicrap D. The molecular characterization of von Willebrand  
579 disease: good in parts. *British journal of haematology*. 2013; **161**: 166-76.  
580 10.1111/bjh.12249.

581 14 van Galen KP, Tuinenburg A, Smeets EM, Schutgens RE. Von Willebrand  
582 factor deficiency and atherosclerosis. *Blood reviews*. 2012; **26**: 189-96.  
583 10.1016/j.blre.2012.05.002.

584 15 Zheng XL. ADAMTS13, TTP and Beyond. *Hereditary genetics : current  
585 research*. 2013; **2**: e104. 10.4172/2161-1041.1000e104.

586 16 Jin SY, Tohyama J, Bauer RC, Cao NN, Rader DJ, Zheng XL. Genetic ablation  
587 of Adamts13 gene dramatically accelerates the formation of early atherosclerosis  
588 in a murine model. *Arteriosclerosis, thrombosis, and vascular biology*. 2012; **32**:  
589 1817-23. 10.1161/ATVBAHA.112.247262.

590 17 Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de  
591 Maat MP, Leebeek FW, Breteler MM. High von Willebrand factor levels increase  
592 the risk of stroke: the Rotterdam study. *Stroke; a journal of cerebral circulation*.  
593 2010; **41**: 2151-6. 10.1161/STROKEAHA.110.586289.

594 18 Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a  
595 component of Weibel-Palade bodies of human endothelial cells. *Blood*. 1989; **73**:  
596 1109-12.

597 19 McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF.  
598 GMP-140, a platelet alpha-granule membrane protein, is also synthesized by  
599 vascular endothelial cells and is localized in Weibel-Palade bodies. *The Journal of  
600 clinical investigation*. 1989; **84**: 92-9. 10.1172/JCI114175.

601 20 Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte  
602 rolling and extravasation are severely compromised in P selectin-deficient mice.  
603 *Cell*. 1993; **74**: 541-54.

604 21 Doyle EL, Ridger V, Ferraro F, Turmaine M, Saftig P, Cutler DF. CD63 is an  
605 essential cofactor to leukocyte recruitment by endothelial P-selectin. *Blood*.  
606 2011; **118**: 4265-73. blood-2010-11-321489 [pii]  
607 10.1182/blood-2010-11-321489.

608 22 Babich V, Knipe L, Hewlett L, Meli A, Dempster J, Hannah MJ, Carter T.  
609 Differential effect of extracellular acidosis on the release and dispersal of soluble  
610 and membrane proteins secreted from the Weibel-Palade body. *The Journal of  
611 biological chemistry*. 2009; **284**: 12459-68.

612 23 Babich V, Meli A, Knipe L, Dempster JE, Skehel P, Hannah MJ, Carter T.  
613 Selective release of molecules from Weibel-Palade bodies during a lingering kiss.  
614 *Blood*. 2008; **111**: 5282-90.

615 24 Cleator JH, Zhu WQ, Vaughan DE, Hamm HE. Differential regulation of  
616 endothelial exocytosis of P-selectin and von Willebrand factor by protease-  
617 activated receptors and cAMP. *Blood*. 2006; **107**: 2736-44. 10.1182/blood-2004-  
618 07-2698.

619 25 Han X, Li P, Yang Z, Huang X, Wei G, Sun Y, Kang X, Hu X, Deng Q, Chen L,  
620 He A, Huo Y, Li D, Betzig E, Luo J. Zyxin regulates endothelial von Willebrand  
621 factor secretion by reorganizing actin filaments around exocytic granules. *Nat  
622 Commun*. 2017; **8**: 14639. 10.1038/ncomms14639.

623 26 Li P, Wei G, Cao Y, Deng Q, Han X, Huang X, Huo Y, He Y, Chen L, Luo J.  
624 Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand  
625 factor. *Blood*. 2017. 10.1182/blood-2017-08-802140.

626 27 Michaux G, Abbitt KB, Collinson LM, Haberichter SL, Norman KE, Cutler  
627 DF. The physiological function of von Willebrand's factor depends on its tubular  
628 storage in endothelial Weibel-Palade bodies. *Developmental cell*. 2006; **10**: 223-  
629 32. 10.1016/j.devcel.2005.12.012.

630 28 Romani de Wit T, Rondaij MG, Hordijk PL, Voorberg J, van Mourik JA. Real-  
631 time imaging of the dynamics and secretory behavior of Weibel-Palade bodies.  
632 *Arteriosclerosis, thrombosis, and vascular biology*. 2003; **23**: 755-61.  
633 10.1161/01.ATV.0000069847.72001.E8.

634 29 Riedl J, Crevenna AH, Kessenbrock K, Yu JH, Neukirchen D, Bista M,  
635 Bradke F, Jenne D, Holak TA, Werb Z, Sixt M, Wedlich-Soldner R. Lifeact: a  
636 versatile marker to visualize F-actin. *Nature methods*. 2008; **5**: 605-7.  
637 10.1038/nmeth.1220.

638 30 Lui-Roberts WW, Collinson LM, Hewlett LJ, Michaux G, Cutler DF. An AP-  
639 1/clathrin coat plays a novel and essential role in forming the Weibel-Palade  
640 bodies of endothelial cells. *The Journal of cell biology*. 2005; **170**: 627-36.

641 31 Blagoveshchenskaya AD, Hannah MJ, Allen S, Cutler DF. Selective and  
642 signal-dependent recruitment of membrane proteins to secretory granules  
643 formed by heterologously expressed von Willebrand factor. *Molecular biology of*  
644 *the cell*. 2002; **13**: 1582-93. 10.1091/mbc.01-09-0462.

645 32 Knop M, Gerke V. Ca<sup>2+</sup> -regulated secretion of tissue-type plasminogen  
646 activator and von Willebrand factor in human endothelial cells. *Biochim Biophys*  
647 *Acta*. 2002; **1600**: 162-7.

648 33 van der Walt S, Schonberger JL, Nunez-Iglesias J, Boulogne F, Warner JD,  
649 Yager N, Gouillart E, Yu T, scikit-image c. scikit-image: image processing in  
650 Python. *PeerJ*. 2014; **2**: e453. 10.7717/peerj.453.

651 34 Tsai W. Moment-preserving thresholding: a new approach. In: O'Gorman  
652 LaK, Rangachar, ed. *Document image analysis* 44-60: IEEE Computer Society  
653 Press Los Alamitos, CA, USA, 1995.

654 35 Team RDC. R: A Language and Environment for Statistical Computing.  
655 www.R-project.org/: the R Foundation for Statistical Computing, 2011.

656 36 Forscher P, Smith SJ. Actions of cytochalasins on the organization of actin  
657 filaments and microtubules in a neuronal growth cone. *The Journal of cell biology*.  
658 1988; **107**: 1505-16.

659 37 Sanders YV, Groeneveld D, Meijer K, Fijnvandraat K, Cnossen MH, van der  
660 Bom JG, Coppens M, de Meris J, Laros-van Gorkom BA, Mauser-Bunschoten EP,  
661 Leebeek FW, Eikenboom J, Wi Nsg. von Willebrand factor propeptide and the  
662 phenotypic classification of von Willebrand disease. *Blood*. 2015; **125**: 3006-13.  
663 10.1182/blood-2014-09-603241.

664 38 Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR,  
665 Mitchison TJ. Dissecting temporal and spatial control of cytokinesis with a  
666 myosin II inhibitor. *Science*. 2003; **299**: 1743-7. 10.1126/science.1081412.

667 39 Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-  
668 D3 domains of von Willebrand factor in Weibel-Palade bodies. *Blood*. 2006; **107**:  
669 3922-4. 10.1182/blood-2005-09-3635.

670 40 Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, Turner  
671 N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin anchors newly released  
672 ultralarge von Willebrand factor multimers to the endothelial cell surface. *Blood*.  
673 2004; **103**: 2150-6. 10.1182/blood-2003-08-2956.



674 41 Kiskin NI, Hellen N, Babich V, Hewlett L, Knipe L, Hannah MJ, Carter T.  
675 Protein mobilities and P-selectin storage in Weibel-Palade bodies. *J Cell Sci.*  
676 2010; **123**: 2964-75. 10.1242/jcs.073593.

677 42 McCormack JJ, Lopes da Silva M, Ferraro F, Patella F, Cutler DF. Weibel-  
678 Palade bodies at a glance. *J Cell Sci.* 2017; **130**: 3611-7. 10.1242/jcs.208033.

679 43 Valentijn KM, van Driel LF, Mourik MJ, Hendriks GJ, Arends TJ, Koster AJ,  
680 Valentijn JA. Multigranular exocytosis of Weibel-Palade bodies in vascular  
681 endothelial cells. *Blood.* 2010; **116**: 1807-16. blood-2010-03-274209 [pii]  
682 10.1182/blood-2010-03-274209.

683 44 Michaux G, Hewlett LJ, Messenger SL, Goodeve AC, Peake IR, Daly ME,  
684 Cutler DF. Analysis of intracellular storage and regulated secretion of 3 von  
685 Willebrand disease-causing variants of von Willebrand factor. *Blood.* 2003; **102**:  
686 2452-8. 10.1182/blood-2003-02-0599.

687 45 Nightingale TD, Cutler DF, Cramer LP. Actin coats and rings promote  
688 regulated exocytosis. *Trends Cell Biol.* 2012; **22**: 329-37. S0962-8924(12)00051-  
689 7 [pii]  
690 10.1016/j.tcb.2012.03.003.

691 46 Miklavc P, Wittekindt OH, Felder E, Dietl P. Ca<sup>2+</sup>-dependent actin coating  
692 of lamellar bodies after exocytotic fusion: a prerequisite for content release or  
693 kiss-and-run. *Annals of the New York Academy of Sciences.* 2009; **1152**: 43-52.  
694 10.1111/j.1749-6632.2008.03989.x.

695 47 Yu HY, Bement WM. Control of local actin assembly by membrane fusion-  
696 dependent compartment mixing. *Nature cell biology.* 2007; **9**: 149-59.  
697 10.1038/ncb1527.

698 48 Lorenzi O, Frieden M, Villemin P, Fournier M, Foti M, Vischer UM. Protein  
699 kinase C-delta mediates von Willebrand factor secretion from endothelial cells in  
700 response to vascular endothelial growth factor (VEGF) but not histamine. *Journal*  
701 *of thrombosis and haemostasis : JTH.* 2008; **6**: 1962-9. 10.1111/j.1538-  
702 7836.2008.03138.x.

703 49 Jabbour G, Lemoine-Morel S, Casazza GA, Hala Y, Moussa E, Zouhal H.  
704 Catecholamine response to exercise in obese, overweight, and lean adolescent  
705 boys. *Medicine and science in sports and exercise.* 2011; **43**: 408-15.  
706 10.1249/MSS.0b013e3181f1bef3.

707 50 Cho W. Membrane targeting by C1 and C2 domains. *The Journal of*  
708 *biological chemistry.* 2001; **276**: 32407-10. 10.1074/jbc.R100007200.

709 51 Khaliulin I, Bond M, James AF, Dyar Z, Amini R, Johnson JL, Suleiman MS.  
710 Functional and cardioprotective effects of simultaneous and individual activation  
711 of protein kinase A and Epac. *Br J Pharmacol.* 2017; **174**: 438-53.  
712 10.1111/bph.13709.

713 52 Yang W, Mei FC, Cheng X. EPAC1 regulates endothelial annexin A2 cell  
714 surface translocation and plasminogen activation. *FASEB J.* 2017.  
715 10.1096/fj.201701027R.

716 53 Aslam M, Tanislav C, Troidl C, Schulz R, Hamm C, Gunduz D. cAMP  
717 controls the restoration of endothelial barrier function after thrombin-induced  
718 hyperpermeability via Rac1 activation. *Physiol Rep.* 2014; **2**.  
719 10.14814/phy2.12175.

720 54 Conte IL, Cookson E, Hellen N, Bierings R, Mashanov G, Carter T. Is there  
721 more than one way to unpack a Weibel-Palade body? *Blood.* 2015; **126**: 2165-7.  
722 10.1182/blood-2015-08-664961.

723 55 Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer  
724 UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells  
725 involves V2 receptors and cAMP. *The Journal of clinical investigation*. 2000; **106**:  
726 107-16. 10.1172/JCI9516.  
727

## 728 **Figure Legends**

729

### 730 **Figure. 1 The actomyosin ring increases the efficiency of VWF string** 731 **formation but has little effect on leukocyte rolling**

732 HUVECs stimulated under flow with histamine (100  $\mu$ M)/adrenalin (10  
733  $\mu$ M)/IBMX (100  $\mu$ M) in the presence or absence of 0.25 $\mu$ M cytochalasin E (CCE)  
734 and fixed for string length analysis (A-C) or perfused with THP-1 leukocytes for  
735 rolling analysis (D) (N=3). (A-B) HUVECs were fixed and stained for VWF before  
736 imaging on a confocal microscope, pictures shown are tile scans of 10 fields of  
737 view. The whole image (i) and with the boxed area magnified (ii) are shown with  
738 a filter added to improve contrast. Scale bar 50  $\mu$ m (C) The lengths of vWF  
739 strings was quantified from three independent experiments (Control; N=13  
740 images, 1346 strings, CCE; N=14 images, 1364 strings). The percentage of strings  
741 less than 25 $\mu$ m, between 25-50 $\mu$ m and longer than 50 $\mu$ m was calculated per  
742 image and SEM shown. (D) The number of interacting THP-1 leukocytes/min  
743 was determined from movies. Each point represents the total number of  
744 interacting leukocytes per one minute movie, with up to two movies acquired  
745 per experiment from stimulated cells. Error bars represent SD. Statistical  
746 significance assessed using Mann-Whitney test (C) and 1-way ANOVA with  
747 Dunnet's multiple comparison test (D). \*  $P \leq 0.05$ .

748

749 **Figure. 2 Different secretagogues release VWF and VWF pro-peptide with**  
750 **differing efficiencies in a manner that is dependent on the actomyosin ring**

751 (A) HUVECs were stimulated with 100 ng/ml PMA for 5 min and fixed using a  
752 procedure optimal for the actin cytoskeleton, co-stained for VWF (red) and  
753 phalloidin (green), and imaged on a confocal microscope. Maximum intensity  
754 projections shown. Boxed regions are shown magnified. Bar 10  $\mu\text{m}$ . (B)  
755 Schematic of WPB exocytosis in the presence or absence of an actomyosin ring.  
756 Small cargo release is ring-independent while VWF release is more efficient in  
757 the presence of the ring. (C) Quantification of PMA (100 ng/ml), histamine (100  
758  $\mu\text{M}$ ) or histamine (100  $\mu\text{M}$ )/adrenalin (10  $\mu\text{M}$ )/IBMX (100  $\mu\text{M}$ )-stimulated (Ci)  
759 VWF or (Cii) pro-peptide secretion, (n=6-9), error bars=SEM. (Ciii) ratio of  
760 stimulated VWF:propeptide release. Boxes represent 25<sup>th</sup>-75<sup>th</sup> percentiles,  
761 whiskers represent minimum and maximum values. (D) Quantification of PMA  
762 (100 ng/ml)-stimulated (Di) VWF or (Dii) pro-peptide secretion in the presence  
763 or absence of 25  $\mu\text{M}$  blebbistatin or 1  $\mu\text{M}$  cytochalasin E, (n=4), error bars=SEM.  
764 (Diii) ratio of stimulated VWF:propeptide release. Error bars=SEM. Statistical  
765 significance assessed using T-Test with Welch's correction (Ci-ii and Di-ii) and  
766 Ratio T-test (Ciii and Diii). \*  $P \leq 0.05$ , \*\*  $P \leq 0.01$  and \*\*\*  $P \leq 0.001$ .

767

768 **Figure. 3 Release of P-selectin from WPB for recruitment to the plasma**  
769 **membrane is partially ring dependent.**

770 The proportion of cell surface to total P-selectin levels was determined by  
771 surface biotinylation and neutravidin pulldown following stimulation with PMA  
772 (100 ng/ml) (A-B), histamine (100  $\mu\text{M}$ ) or histamine (100  $\mu\text{M}$ )/adrenalin (10  
773  $\mu\text{M}$ )/IBMX (100  $\mu\text{M}$ ) (A) or following PMA stimulation or in the presence or

774 absence of 25  $\mu$ M blebbistatin or 1  $\mu$ M CCE (B). Quantification of western blots  
775 shown (C) PMA n=11, his n=3, HAI n=6, (D) n=12. (C-D) Error bars=SEM.  
776 Statistical significance assessed using T-Test with Welch's correction (C-D). \*  
777  $P \leq 0.05$ , \*\*  $P \leq 0.01$  (E) Schematic of WPB exocytosis in the presence or absence of  
778 an actomyosin ring. NMMII=non-muscle myosin II.

779

780 **Figure. 4 Actin ring recruitment is secretagogue and time dependent.**

781 HUVECs were nucleofected with mCherry-PselectinLum domain and lifeactGFP  
782 and imaged with a spinning-disk confocal microscope in the presence of 100  
783 ng/ml PMA (n=9), 100  $\mu$ M histamine (n=7) or 100  $\mu$ M histamine/10  $\mu$ M  
784 adrenalin/100  $\mu$ M IBMX (n=8). Z stacks were acquired at a spacing of 0.5  $\mu$ m  
785 every 5 s for 10 min. (A) The frequency of fusion events with (positive +ve) or  
786 without an actin ring (negative -ve) at each time-point is plotted. (B) The  
787 percentage of actin ring-positive (+ve) or negative events (-ve) compared to the  
788 total number of events is plotted.

789

790 **Figure 5. High-throughput analysis of exocytic events.**

791 (A) HUVECs were unstimulated or stimulated with 100ng/ $\mu$ l PMA for 10 minutes  
792 followed by staining for external VWF, plasma membrane with wheat germ  
793 agglutinin (WGA) and the nucleus (DAPI). Nine fields of view were acquired per  
794 well, and eight wells imaged per condition. External VWF was segmented using a  
795 custom-designed program. Boxed areas on the VWF channel are shown inverted  
796 and at higher magnification as examples of segmented sites typically acquired  
797 from unstimulated and PMA-stimulated cells. Scale bar 20 $\mu$ m. (B) Schematic of  
798 external antibody labelling protocol to differentiate between actomyosin-

799 dependent and independent exocytosis. NMMII=non-muscle myosin II. (C)  
800 HUVECs stimulated with either histamine (100  $\mu$ M) or PMA (100 ng/ml) were  
801 fixed following 2-20 minutes of stimulation. The number of segmented external  
802 exocytic sites was calculated for each well (the sum of nine fields of view) for  
803 each time point and mean and standard error plotted (N=8 wells). A  
804 representative experiment is shown from N=4 independent experiments. (D & E)  
805 HUVECs were stimulated for 10 min with PMA (100 ng/ml) or histamine (100  
806  $\mu$ M) or left unstimulated. The mean number of exocytic sites per cell per well (D)  
807 (N=8 wells, a representative experiment is shown from N=3 independent  
808 experiments) and the median area per site (E) (N=9-16 independent  
809 experiments) is shown. Bars represent SEM. (F & G) HUVEC were untreated or  
810 pre-treated with blebbistatin (25  $\mu$ M) or CCE (1  $\mu$ M) for 15 min before  
811 stimulation with histamine and PMA. The mean number of sites per cell (F) (N=3  
812 independent experiments) and the proportion of sites with area greater than 2  
813  $\mu$ m<sup>2</sup> (G) (N=8 wells, a representative experiment from N=3 independent  
814 experiments is shown). Boxes represent 25<sup>th</sup>-75<sup>th</sup> percentiles, whiskers  
815 represent minimum and maximum values. Statistical significance was assessed  
816 using 2-way ANOVA with sidak's multiple comparison test (C & G), or 1-way  
817 ANOVA with Tukey's multiple comparison test (E). \* P $\leq$ 0.05, \*\* P $\leq$ 0.01, \*\*\*  
818 P $\leq$ 0.001, \*\*\*\* $\leq$ 0.0001.

819

820 **Figure 6. Analysis of actin ring function with a variety of secretagogues.**

821 HUVECs were treated with or without 1 $\mu$ M CCE before being stimulated with  
822 100ng/ $\mu$ l PMA, 100 $\mu$ M histamine, 1U/ml thrombin, 10 $\mu$ M adrenalin/100  $\mu$ M  
823 IBMX 100  $\mu$ M histamine/10 $\mu$ M adrenalin/100 $\mu$ M IBMX, 10 $\mu$ M forskolin/100  $\mu$ M

824 IBMX, or 40ng/ml VEGF for 10 minutes, followed by staining for external VWF  
825 and the nucleus. Nine fields of view were acquired per well, and eight wells  
826 imaged per condition. Data from representative experiments shown (A-C) (N=3)  
827 and the mean of 3-7 experiments (D). (A) Mean number of exocytic sites per cell  
828 per well following secretagogue stimulation. Bars are SEM. (N=8 wells). (B)  
829 Cumulative frequency graph shows the distributions of the area of exocytic sites.  
830 (C) The mean proportion of exocytic VWF-positive sites with area greater than  
831  $2\mu\text{m}^2$  was calculated following stimulation with various secretagogues with and  
832 without CCE ( $1\mu\text{M}$ ). Boxes represent 25<sup>th</sup>-75<sup>th</sup> percentiles, whiskers represent  
833 minimum and maximum values. N=8 wells. (D) The mean proportion of exocytic  
834 sites with area greater than  $2\mu\text{m}^2$  following stimulation with a number of  
835 secretagogues in the presence of CCE normalised to the mean proportion of large  
836 sites in control samples. Mean value is derived from the n=8 wells per  
837 experiment (n=3-7). Statistical significance assessed between stimulated and  
838 unstimulated distributions using Two sample Kolmogorov-Smirnov test (B), 2-  
839 way ANOVA with Sidak's multiple comparison test (C) and 1-way ANOVA with  
840 Dunnet's multiple comparisons test (D) \*  $P\leq 0.05$ , \*\*  $P\leq 0.005$ , \*\*\*  $P\leq 0.001$ , \*\*\*\*  
841  $P\leq 0.0001$ , @  $P\leq 10^{-15}$ .

842

843 **Figure. 7 The role of protein kinase C isoforms in actin ring recruitment and**  
844 **VWF secretion.**

845 (A, B) HUVECs were nucleofected with PKC $\alpha$ GFP (A) or PKC $\delta$ GFP (B) and  
846 stimulated for 5 min with 100 ng/ml PMA, fixed in formaldehyde with a  
847 procedure optimal for the actin cytoskeleton, co-stained for VWF (blue) and  
848 phalloidin (red) and imaged on a confocal microscope. Image shown is a

849 maximum intensity projection, boxed regions are shown magnified. Bar 10  $\mu\text{m}$ .  
850 (C, D) HUVECs were nucleofected with 2 rounds of 200 pmol siRNA against  
851 PKC $\alpha$ ,  $\delta$  or both isoforms together and either (C) the samples were prepared for  
852 western blot or (D) VWF secretion monitored. (E) HUVEC were treated with 1 $\mu\text{M}$   
853 GÖ6976 and then stimulated with PMA (100ng/ml), histamine (100 $\mu\text{M}$ ) or a  
854 combination of histamine (100 $\mu\text{M}$ ), adrenalin (10 $\mu\text{M}$ ) and IBMX (100 $\mu\text{M}$ ). VWF  
855 secretion was monitored and results are shown normalised to the uninhibited  
856 sample. The PKC inhibitor has the greatest effect on PMA-stimulated release and  
857 a lesser effect on hist/ad/IBMX. n=4, error bars=SEM. Statistical significance  
858 assessed using T-Test with Welch's correction. \* P<0.05 and \*\* P<0.01.

859

860

861 **Video 1. Rolling analysis of untreated endothelial cells.**

862 Unstimulated HUVECs were perfused with THP-1 leukocytes.

863

864 **Video 2. Rolling analysis of endothelial cells stimulated with Histamine and**  
865 **Adrenalin.**





866 HUVECs were stimulated under flow with Histamine (100  $\mu\text{M}$ )/Adrenalin (10  
867  $\mu\text{M}$ )/IBMX (100  $\mu\text{M}$ ) and perfused with THP-1 leukocytes.

868





869 **Video 3. Rolling analysis untreated endothelial cells.**





870 HUVECs were stimulated under flow with Histamine (100  $\mu\text{M}$ )/Adrenalin (10  
871  $\mu\text{M}$ )/IBMX (100  $\mu\text{M}$ ) in the presence of 0.25 $\mu\text{M}$  cytochalasin E (CCE) and  
872 perfused with THP-1 leukocytes.







873
























**A****B****C****D****E**






**A(i)****B(i)****C(i)****D**






A



**Figure. S1 P-selectin localisation at exocytosis**


HUVECs were stimulated with 100 ng/ml PMA for 20 min and labelled without permeabilisation for surface VWF (red), P-selectin (green), alongside the nucleus (blue) and imaged on a confocal microscope. Images shown are maximum intensity projections. Bar 10  $\mu$ m.



**Figure. S2 High-throughput analysis of exocytic events.**


HUVECs were stimulated with 100ng/ml PMA for 10 minutes, or left unstimulated followed by staining for external VWF, plasma membrane with wheat germ agglutinin (WGA) and the nucleus (DAPI). Images were acquired using the Opera high-content screening (PerkinElmer) confocal microscope. Nine fields of view were acquired per well, and eight wells imaged per condition. External VWF was segmented using a custom-designed program. (A) HUVECs were stimulated with serial dilutions of PMA (100ng/ml – 6.25ng/ml) for 10 minutes and the number and area of segmented external exocytic sites measured. The average number of exocytic sites per cell (Aa) and average proportion of exocytic sites with area greater than  $2\mu\text{m}^2$  (Ab) is shown. Bar represent SEM (n=4). Statistical significance was assessed using 1-way ANOVA with Tukey's multiple comparison test (Ab) and no significant difference is seen between any concentration of PMA. (B) HUVEC were pre-treated with blebbistatin (25  $\mu\text{M}$ ) or CCE (1  $\mu\text{M}$ ) for 15 min before stimulation with histamine and PMA. The mean proportion of larger (area greater than  $2\mu\text{m}^2$ ) exocytic sites in blebbistatin or CCE-treated cells (derived from the mean of 8 wells per experiment) was normalised to the proportion of large sites in control samples, per experiment (N=3 independent experiments). Statistical significance was assessed with 2-way ANOVA sidak's multiple comparison test , \*\* P<0.05 and \*\*\* P<0.005.






**Figure S3. Analysis of actin ring function with a variety of secretagogues.**

HUVECs were treated with or without 1 $\mu\text{M}$  CCE before being stimulated with either 40ng/ml VEGF alone or in combination (A, C, E), 100 $\mu\text{M}$  histamine alone or in combination (B, D, F) or 100ng/ $\mu\text{l}$  PMA (A-F) for 10 minutes, followed by staining for external VWF and the nucleus. Images were acquired using the Opera high-content screening confocal microscope. Nine fields of view were acquired per well, and eight wells imaged per condition. Representative experiments are shown (A-D) from N=3 (A, C) and N=4 (B, D) independent experiments. (A-B) Mean number of exocytic sites per cell per well with the different secretagogue combinations. Bars represent SEM. (N=8 wells). (C-D) The proportion of VWF sites greater than 2 $\mu\text{m}^2$  following stimulation with secretagogues alone or in combination and with or without CCE (1 $\mu\text{M}$ ). Boxes represent 25th-75th percentiles, whiskers represent minimum and maximum values. (N=8 wells). (E-F) The mean proportion of exocytic sites with area greater than 2 $\mu\text{m}^2$  following stimulation with a number of secretagogues in the presence of CCE normalised to the mean proportion of large sites in control samples. Bars represent SEM. Mean value is derived from the mean of N=8 wells per experiment (E; N=3, F; N=4). Statistical significance was assessed using 2-way ANOVA with Sidak's multiple comparison test (C-D) or 1-way ANOVA with Dunnet's multiple comparisons test (E-F). \* P<0.05, \*\*\*\* P<0.0001, ns=not significant.



**Figure. S4 The timing of PKC delta recruitment to exocytic sites**

HUVECs were nucleofected with mcherry-Pselectin.lum and PKCdGFP or mcherry-Pselectin.lum and lifeact GFP and imaged with a spinning-disk confocal microscope in the presence of 100 ng/ml PMA (n=9). Z stacks were acquired at a spacing of 0.5  $\mu$ m every 5 s for 10 min. The timing of actin and PKC delta recruitment was plotted relative to the point of fusion (as determined by the loss of mcherry-Pselectin.lum).



**Figure S5. Effect of GÖ6976 on exocytic site size and number.**

HUVECs were treated with or without 1 $\mu$ M GÖ6976 for 15 minutes before being stimulated with 100ng/ $\mu$ l PMA, 100 $\mu$ M Histamine or 100 $\mu$ M Histamine/10 $\mu$ M adrenalin/100 $\mu$ M IBMX for 10-30 minutes. The VWF secretion was determined by ELISA (30 minutes stimulation) (A) or following 10 minutes stimulation, samples were stained for external VWF, wheat germ agglutinin (WGA) to label the plasma membrane with or DAPI to label the nucleus. Images were acquired using the Opera high-content screening (PerkinElmer) confocal microscope. Nine fields of view were acquired per well, and eight wells imaged per condition. Data from a representative experiment is shown (n=4) (B,C). (A) The amount of VWF released is determined relative to cells stimulated with Histamine (B) Mean number of exocytic sites/cell with the different secretagogues in the presence or absence of GÖ6976. (C) The proportion of exocytic sites greater than 2 $\mu$ m<sup>2</sup> with different secretagogues in the presence of GÖ6976 normalised to an untreated control.